422 related articles for article (PubMed ID: 33248905)
1. Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer.
Sautès-Fridman C; Verneau J; Sun CM; Moreira M; Chen TW; Meylan M; Petitprez F; Fridman WH
Semin Immunol; 2020 Apr; 48():101406. PubMed ID: 33248905
[TBL] [Abstract][Full Text] [Related]
2. Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies.
Trüb M; Zippelius A
Front Immunol; 2021; 12():674565. PubMed ID: 34054861
[TBL] [Abstract][Full Text] [Related]
3. [Intratumoral B cells and tertiary lymphoid structures are biomarkers of survival and immunotherapy responses].
Fridman WH; Petitprez F; Sautes-Fridman C
Bull Cancer; 2020 Apr; 107(4):403-404. PubMed ID: 32284150
[No Abstract] [Full Text] [Related]
4. Targeting Tertiary Lymphoid Structures for Tumor Immunotherapy.
Tang H; Qiu X; Timmerman C; Fu YX
Methods Mol Biol; 2018; 1845():275-286. PubMed ID: 30141019
[TBL] [Abstract][Full Text] [Related]
5. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts.
Rodriguez AB; Peske JD; Woods AN; Leick KM; Mauldin IS; Meneveau MO; Young SJ; Lindsay RS; Melssen MM; Cyranowski S; Parriott G; Conaway MR; Fu YX; Slingluff CL; Engelhard VH
Cell Rep; 2021 Jul; 36(3):109422. PubMed ID: 34289373
[TBL] [Abstract][Full Text] [Related]
6. Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies.
N J; J T; Sl N; Gt B
Oncoimmunology; 2021 Mar; 10(1):1900508. PubMed ID: 33854820
[TBL] [Abstract][Full Text] [Related]
7. Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation.
Domblides C; Rochefort J; Riffard C; Panouillot M; Lescaille G; Teillaud JL; Mateo V; Dieu-Nosjean MC
Front Immunol; 2021; 12():698604. PubMed ID: 34276690
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Induction of Tertiary Lymphoid Structures in Cancer Through Stromal Remodeling.
Johansson-Percival A; Ganss R
Front Immunol; 2021; 12():674375. PubMed ID: 34122434
[TBL] [Abstract][Full Text] [Related]
9. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers.
Dieu-Nosjean MC; Giraldo NA; Kaplon H; Germain C; Fridman WH; Sautès-Fridman C
Immunol Rev; 2016 May; 271(1):260-75. PubMed ID: 27088920
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation.
Salem D; Chelvanambi M; Storkus WJ; Fecek RJ
Front Immunol; 2021; 12():629519. PubMed ID: 33746966
[TBL] [Abstract][Full Text] [Related]
11. Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Cabrita R; Lauss M; Sanna A; Donia M; Skaarup Larsen M; Mitra S; Johansson I; Phung B; Harbst K; Vallon-Christersson J; van Schoiack A; Lövgren K; Warren S; Jirström K; Olsson H; Pietras K; Ingvar C; Isaksson K; Schadendorf D; Schmidt H; Bastholt L; Carneiro A; Wargo JA; Svane IM; Jönsson G
Nature; 2020 Jan; 577(7791):561-565. PubMed ID: 31942071
[TBL] [Abstract][Full Text] [Related]
12. Tertiary lymphoid structures in the era of cancer immunotherapy.
Sautès-Fridman C; Petitprez F; Calderaro J; Fridman WH
Nat Rev Cancer; 2019 Jun; 19(6):307-325. PubMed ID: 31092904
[TBL] [Abstract][Full Text] [Related]
13. STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development.
Filderman JN; Appleman M; Chelvanambi M; Taylor JL; Storkus WJ
Front Immunol; 2021; 12():690105. PubMed ID: 34054879
[TBL] [Abstract][Full Text] [Related]
14. Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers.
Seow DYB; Yeong JPS; Lim JX; Chia N; Lim JCT; Ong CCH; Tan PH; Iqbal J
Breast Cancer Res Treat; 2020 Apr; 180(2):369-377. PubMed ID: 32034580
[TBL] [Abstract][Full Text] [Related]
15. Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors.
Zhang WH; Wang WQ; Han X; Gao HL; Xu SS; Li S; Li TJ; Xu HX; Li H; Ye LY; Lin X; Wu CT; Long J; Yu XJ; Liu L
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33055204
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Associated Tertiary Lymphoid Structures: A Cancer Biomarker and a Target for Next-generation Immunotherapy.
Dieu-Nosjean MC
Adv Exp Med Biol; 2021; 1329():51-68. PubMed ID: 34664233
[TBL] [Abstract][Full Text] [Related]
17. Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy.
Rodriguez AB; Engelhard VH
Cancer Immunol Res; 2020 Nov; 8(11):1338-1345. PubMed ID: 33139300
[TBL] [Abstract][Full Text] [Related]
18. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
[TBL] [Abstract][Full Text] [Related]
19. Tertiary lymphoid structures in cancer: maturation and induction.
Chen Y; Wu Y; Yan G; Zhang G
Front Immunol; 2024; 15():1369626. PubMed ID: 38690273
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of tertiary lymphoid structure formation: cooperation between inflammation and antigenicity.
Khanal S; Wieland A; Gunderson AJ
Front Immunol; 2023; 14():1267654. PubMed ID: 37809103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]